BioSpace News Archive

Deals

Ligand’s New Antibody Business Prepares to Hit the Nasdaq

Ligand will spin off its antibody discovery business into a new entity known as OmniAb, Inc., which will then merge with Avista Capital Partners and head to The Nasdaq Stock Market.

March 24, 2022
·
2 min read
·
Alex Keown
Drug Development

Research Roundup: Halting Memory Loss in Alzheimer’s, COVID-19 and Diabetes

A recent study in mice was able to halt memory decay in a model of Alzheimer’s disease. Another study found that even mild infection increased the risk of new-onset type 2 diabetes, although the risk increased with the severity of COVID-19.

March 24, 2022
·
5 min read
·
Mark Terry
Business

Orion Honing in on Cancer and Pain in Shift Away From Neuro

Orion Corporation announced its plans to shift focus to new proprietary drugs in oncology and pain, expecting to cut 37 jobs.

March 24, 2022
·
3 min read
·
Mark Terry
Business

BioSpace Movers & Shakers, March 25

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

March 24, 2022
·
7 min read
·
Alex Keown
Drug Development

Stalled by COVID-19, TB Research Needs to Make Up for Lost Time

In honor of March 24, World TB Day, BioSpace looks at clinical trials and eradication efforts occurring today.

March 24, 2022
·
5 min read
·
Rosemary Scott
Policy

Automation in Pharmaceutical Industry Makes it a Prime Target for Cyber Attacks: Be Ready

Automation in pharmaceutical industry can make the companies target of the cyber threats emanating from Russia, China, and North Korea. It can be collateral or direct.

March 24, 2022
·
5 min read
·
Gail Dutton
Drug Development

AstraZeneca’s Imfinzi Fails to Boost Survival in Cervical Cancer

AstraZeneca shared that using imfinzi alongside chemoradiotherapy did not meet statistical significance in improving progression-free survival versus using CRT alone.

March 24, 2022
·
2 min read
·
Vanessa Doctor, RN
FDA

Pfizer Notches Breakthrough Status in Race to an RSV Vaccine

Pfizer has announced it received Breakthrough Therapy Designation from the FDA for its vaccine candidate intended to prevent infections caused by the respiratory syncytial virus (RSV).

March 24, 2022
·
3 min read
·
Hayley Shasteen
Drug Development

Jazz Doses First Patient in Broad Trial for Promising Cancer Drug

The Phase II trial is evaluating zepzelca as a monotherapy in patients with urothelial carcinoma, large cell neuroendocrine carcinoma of the lung and HRD tumors.

March 24, 2022
·
3 min read
·
Hayley Shasteen
Policy

U.S. Judge Tosses Genentech Lawsuit Against Sandoz

A federal judge in Delaware tossed out a lawsuit by Genentech, Inc., a Roche company, accusing Novartis’ Sandoz division of patent infringement.

March 24, 2022
·
3 min read
·
Mark Terry